Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNF , preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.

Данное издание не является оригинальным. Книга печатается по технологии принт-он-деманд после получения заказа.